Chimeric Therapeutics Ltd. (AU:CHM) has released an update.
Chimeric Therapeutics Ltd., an innovative Australian cell therapy company, has announced receiving ethics approval to commence a Phase 1/2 clinical trial for its novel CHM CDH17 CAR T cell therapy, aimed at treating advanced gastrointestinal cancers. The approval is a critical step towards starting the trial under FDA regulations, with the preclinical studies showing promising results, including complete tumor eradication in seven cancer models without harming normal tissue. Chimeric Therapeutics continues to advance its diverse portfolio, focusing on the development and commercialization of groundbreaking cell therapies for oncology.
For further insights into AU:CHM stock, check out TipRanks’ Stock Analysis page.
